Latest Breaking News On - Bayer nexavar - Page 2 : comparemela.com

Kazia Therapeutics Ltd s upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research

Kazia Therapeutics Ltd s upcoming top-line data for EVT801 expected to be a share price catalyst: Edison Investment Research
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

Novarti votrientBayer nexavarEdison investment researchKazia therapeutics ltdCancer research communicationsEdison investmentCancer research

3 Healthcare Stocks You Can Target

Owning these healthcare stocks could be rewarding during market uncertainty.

Buffett berkshire hathwayBristol myer squibbStifel nicolausWarren buffettStephen guilfoyleBret jensenBayer nexavarMckesson coFederal reserveNational comprehensive cancer networkCancer therapy company is smallTrade has my attentionBerkshire hathwayOption look bigMoney proAll smarts

Fierce Pharma Asia—Lilly-Abbisko cardiometabolic pact; Daiichi Sankyo asset sale; Eisai s next Alzheimer s prospect

Eli Lilly penned a $258 million R&D pact with Abbisko Therapeutics. Daiichi Sankyo sold U.S. cardiovascular drugs to Cosette Pharma. Eisai's neurology chief talked about its Aduhelm follow-on drug. And more.

Ridgeback biotherapeuticIvan cheungDaiichi sankyoEli lillyKen kellerBayer nexavarFosun pharmaMerck coStanford universityAbbisko therapeuticsCosette pharmaFierce biotechBiogen partnered alzheimerAccuredit therapeuticsUnited nations backed medicines patent poolDaiichi sankyo

AstraZeneca s Imfinzi strikes immunotherapy s first win in bile duct cancer, with Merck s Keytruda behind

While other cancer immunotherapies are busy expanding into different tumor types, AstraZeneca’s Imfinzi has been a lung cancer story. But the company is now trumpeting a first-of-its-kind win for the drug in bile duct cancer, ahead of Merck’s Keytruda.

Soult ukpyolsiSouth koreaUnited statesAstrazeneca imfinziServier tibsovoMerck keytrudaBristol myers squibb opdivoIncyte pemazyreSusan galbraithBayer nexavarSeoul national university hospitalMerck coSouth americaBristol myers squibbDaiichi sankyo partnered enhertuMerck partnered lynparza

Fierce Pharma Asia—Biogen-Eisai s Alzheimer s drug filing; Samsung-Roche deal growth; Sunovion-Otsuka neuro pact

Biogen and Eisai have started an FDA rolling submission for another Alzheimer's disease drug. Samsung Biologics' long-term partnership with Roche has grown in value. Otsuka has penned a near-$1 billion deal for four Sunovion neuropsychiatric candidates. And more.

South koreaSouth koreanSumitomo dainippon pharmaSecura bioSamsung biologicsAurobindo pharmaBayer nexavarViiv healthSumitomo dainipponViatris partnered semgleeSamsung biologicsSumitomo dainippon pharmaSunovion pharmaceuticalsOtsuka pharmaceuticalJcr pharmaceuticalsViiv healthcare